TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1890008

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 15
Study: 4042800

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exercise intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Diet plus exercise intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 65
Study: 31433809

Group type: EXPERIMENTAL
Intervention: 8 oz. pomegranate juice
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (8 oz. polyphenol-free juice)
Number of subjects: 77
Study: 29249596

Group type: EXPERIMENTAL
Intervention: Telephone counseling by pharmacist bi-monthly for one year
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 164
Study: 27421877

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 10
Study: 24633717

Group type: EXPERIMENTAL
Intervention: Adherence Support Program (ASP)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 889
Study: 22401804

Group type: EXPERIMENTAL
Intervention: Encapsulated curcumin (ECB)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Encapsulated curcumin plus other polyphenols (ECBB)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Free curcumin (FCB)
Number of subjects: 3
Study: 20048680

Group type: EXPERIMENTAL
Intervention: Provider-focused intervention (report given to physician before visit with adherence data)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Provider-focused intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control visits
Number of subjects: 156
Study: 17490976

Group type: EXPERIMENTAL
Intervention: Iron and riboflavin supplementation (30 mg Fe and 6 mg riboflavin) with vitamin A-fortified rice
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo control (VA only)
Number of subjects: 38
Study: 15935958

Group type: EXPERIMENTAL
Intervention: Bipolar electrode configuration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laplacian electrode configuration
Number of subjects: 10
Study: 12925454

Group type: EXPERIMENTAL
Intervention: Pexelizumab 2.0‐mg/kg bolus
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Pexelizumab 2.0‐mg/kg bolus and 0.05‐mg/kg per h infusion for 20 hours
Number of subjects: 960

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960
Study: 10813280

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 64
Study: 9122580

Group type: EXPERIMENTAL
Intervention: Surgical therapy (uvulopalatopharyngoplasty (UPPP), nasal surgery, maxillofacial surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 0
Study: 1513833

Group type: EXPERIMENTAL
Intervention: Foamed gel dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 0
Study: 6186852

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of acebutolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Twice-a-day dosing of acebutolol
Number of subjects: 26
Study: 30141338

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate communication strategies (storytelling or visual presentation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Perception of mothers' intention on HPV vaccination
Number of subjects: 19

Group type: COMPARATOR
Intervention: Current practice of using information-based written materials
Number of subjects: 19
Study: 31724343

Group type: EXPERIMENTAL
Intervention: Formulation AH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation AK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference (single-entity tablets)
Number of subjects: 0
Study: 29891263

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation with hippocampus avoidance (PCI-HA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard prophylactic cranial irradiation (PCI)
Number of subjects: 150
Study: 28776077

Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (100 mg in fasted state)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (200 mg in fasted state)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (200 mg in fed state)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Zytiga (1000 mg)
Number of subjects: 11
Study: 26140829

Group type: EXPERIMENTAL
Intervention: White light imaging followed by narrow band imaging (WL/NBI)
Number of subjects: 148

Group type: COMPARATOR
Intervention: White light imaging only (WL/WL)
Number of subjects: 148
Study: 23640558

Group type: EXPERIMENTAL
Intervention: Exercise training (individually tailored, supervised, for six weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comparison between groups after six weeks
Number of subjects: 48
Study: 21703101

Group type: EXPERIMENTAL
Intervention: Intranasal carbon dioxide (CO(2))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment (no CO(2))
Number of subjects: 12
Study: 18489933

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 150
Study: 17178269

Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 14652643

Group type: EXPERIMENTAL
Intervention: Prolonged Certoparin application
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 11064980

Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 296

Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 296
Study: 8976308

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest without needles being inserted
Number of subjects: 10
Study: 1291203

Group type: EXPERIMENTAL
Intervention: Formula-fed with supplementary zinc 1.14-2.28 mg/kg/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Formula-fed and supplemented with Vitamin B complex as placebo
Number of subjects: 102
Study: 6439639

Group type: EXPERIMENTAL
Intervention: Hyperosmolar basic nutrition solution (3% amino acids, carbohydrates and electrolytes, 806 mosm/l)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoosmolar electrolyte solution (299 mosm/l)
Number of subjects: 24
Study: 29528793

Group type: EXPERIMENTAL
Intervention: Fruquintinib (5 mg once daily in 4-week cycles of 3 weeks on, 1 week off)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 25341680

Group type: EXPERIMENTAL
Intervention: Individualized education programme in addition to standard care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 25312546

Group type: EXPERIMENTAL
Intervention: Intervention group receiving feedback regarding assessment results and recommendations for subsequent treatment.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group receiving treatment as usual and global feedback regarding assessment results without recommendations.
Number of subjects: 286
Study: 24144944

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN‐100)
Number of subjects: 4683

Group type: EXPERIMENTAL
Intervention: Plasma PAA:PAGN ratio
Number of subjects: 4683
Study: 21243280

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no massage therapy)
Number of subjects: 40
Study: 18456137

Group type: EXPERIMENTAL
Intervention: Immediately loaded OMIs (up to 250 g of direct force applied immediately)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Delayed loaded OMIs (loaded 3 to 5 weeks later)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Loaded OMIs (combined)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unloaded OMIs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pain during OMI placement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pain during OMI removal
Number of subjects: 13
Study: 17080220

Group type: EXPERIMENTAL
Intervention: Insulin treatment for glycaemic control
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-diabetic subjects (reference group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 20
Study: 11802928

Group type: EXPERIMENTAL
Intervention: Questionnaire with intimate questions; Sample mailed to laboratory
Number of subjects: 750

Group type: COMPARATOR
Intervention: Questionnaire without intimate questions; Sample mailed to laboratory
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sample delivered to physician's office (men)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sample mailed to laboratory (women)
Number of subjects: 750
Study: 10030506

Group type: EXPERIMENTAL
Intervention: Electronic treatment suggestions for heart failure, ischemic heart disease, reactive airways disease, and uncomplicated hypertension.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no access to electronic treatment suggestions).
Number of subjects: 28
Study: 7554309

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Number of subjects: 63
Study: 2256971

Group type: EXPERIMENTAL
Intervention: One-injection-site peribulbar anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 100
Study: 6445180

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 165
Study: 29945252

Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 (single dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: L-AmB 3 mg/kg/day for 14 days (control)
Number of subjects: 80
Study: 27465063

Group type: EXPERIMENTAL
Intervention: End-task feedback (ET)
Number of subjects: 65

Group type: COMPARATOR
Intervention: In-task feedback (IT)
Number of subjects: 65
Study: 26360284

Group type: EXPERIMENTAL
Intervention: D-serine (60 mg/kg) given orally in divided daily doses for 16 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24335106

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 846

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 846
Study: 22531678

Group type: EXPERIMENTAL
Intervention: pH1N1/09 case definition for influenza exposure
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Influenza exposure
Number of subjects: 19
Study: 19400023

Group type: EXPERIMENTAL
Intervention: Pain and dorsiflexion range of motion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fracture management, fracture severity, baseline activity limitation, pain, mobility and dorsiflexion range of motion
Number of subjects: 150
Study: 17304425

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 weeks of age
Number of subjects: 68

Group type: COMPARATOR
Intervention: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 4 weeks of age
Number of subjects: 68
Study: 15216537

Group type: EXPERIMENTAL
Intervention: Fractional photothermolysis (FP) with micro‐exposures of variable MTZ density on forearms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fractional photothermolysis (FP) on periorbital area
Number of subjects: 45
Study: 11114277

Group type: EXPERIMENTAL
Intervention: Progressive strength training (FM(T))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (FM(C))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy training group (H(T))
Number of subjects: 21
Study: 10206032

Group type: EXPERIMENTAL
Intervention: 8 mg of 1% hyperbaric bupivacaine injected over 40 sec (Group SLOW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 mg of 1% hyperbaric bupivacaine injected over 3 sec (Group FAST)
Number of subjects: 30
Study: 7798076

Group type: EXPERIMENTAL
Intervention: Pull-out program for gifted students
Number of subjects: 60
Study: 2129376

Group type: EXPERIMENTAL
Intervention: 750,000 and 1.5 mio U streptokinase (SK)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200,000 U urokinase (UK) and 4.5 mio U pro‐urokinase (PUK)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SK groups (750,000 and 1.5 mio U)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BRL 26921
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SK
Number of subjects: 40
Study: 520990

Group type: EXPERIMENTAL
Intervention: 40 mg daily etiroxate hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg daily etiroxate hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: etiroxate hydrochloride
Number of subjects: 0
Study: 31826936

Group type: EXPERIMENTAL
Intervention: Long-detection time (NID 30/40)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Nominal detection time (NID 18/24)
Number of subjects: 1902
Study: 31755625

Group type: EXPERIMENTAL
Intervention: Standard treatment - on target (below 130 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment - on target (below 140 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive treatment - on target
Number of subjects: 0
Study: 28485075

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma Exchange (PE)
Number of subjects: 20
Study: 26509147

Group type: EXPERIMENTAL
Intervention: CE model with treatment effect
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo subjects
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sparse sampling
Number of subjects: 3
Study: 24624861

Group type: EXPERIMENTAL
Intervention: 6% Voluven (HES 130/0.4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% NaCl (normal saline solution)
Number of subjects: 0
Study: 20921019

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Non-Invasive Positive Pressure Ventilation (NIPPV)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Standard Oxygen Therapy
Number of subjects: 1069
Study: 19819210

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 137
Study: 18024876

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin chemotherapy (NACT) before radiotherapy (RT) or chemoradiotherapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxane-containing regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by RT or CRT
Number of subjects: 0
Study: 12925047

Group type: EXPERIMENTAL
Intervention: Prediabetic pregnancies
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Post-diabetic pregnancies
Number of subjects: 913

Group type: COMPARATOR
Intervention: Non-diabetic pregnancies (control)
Number of subjects: 913
Study: 10499382

Group type: EXPERIMENTAL
Intervention: Hypnosedation (hypnosis in combination with conscious IV sedation and local anaesthesia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal alertness
Number of subjects: 0
Study: 8877349

Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg/day)
Number of subjects: 36
Study: 1496699

Group type: EXPERIMENTAL
Intervention: Chloroquine base 25 mg/kg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Amodiaquine base 25 mg/kg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine plus 3 days of quinine
Number of subjects: 98
Study: 6357536

Group type: EXPERIMENTAL
Intervention: Dobutamine (n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% dextrose in water (n = 7)
Number of subjects: 15
Study: 2948270

Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zimelidine (100 mg)
Number of subjects: 10
Study: 29520872

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a 180 μg/wk × 48 weeks (group 4)
Number of subjects: 383

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 90 μg/wk × 24 weeks (group 1)
Number of subjects: 383

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 90 μg/wk × 48 weeks (group 3)
Number of subjects: 383

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 180 μg/wk × 24 weeks (group 2)
Number of subjects: 383
Study: 27549751

Group type: EXPERIMENTAL
Intervention: Telehealth-supported care
Number of subjects: 26

Group type: COMPARATOR
Intervention: Specialist nursing intervention
Number of subjects: 26
Study: 24738461

Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin + 5 mg solifenacin (mild obstruction symptom group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin (mild obstruction symptom group)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin + 5 mg solifenacin (moderate obstruction symptom group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin (moderate obstruction symptom group)
Number of subjects: 166
Study: 22939276

Group type: EXPERIMENTAL
Intervention: ArterX Vascular Sealant (AVS)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Gelfoam Plus (Control)
Number of subjects: 217
Study: 20732607

Group type: EXPERIMENTAL
Intervention: Chest compression-only CPR
Number of subjects: 213

Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 213
Study: 19034105

Group type: EXPERIMENTAL
Intervention: Adenosine (25, 50, 100, or 200 microg x kg x min)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 16157899

Group type: EXPERIMENTAL
Intervention: NT-3 (150 microg/kg, subcutaneously, three times a week for 6 months)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12960539

Group type: EXPERIMENTAL
Intervention: General anesthesia (n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (n = 35)
Number of subjects: 70
Study: 10469854

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d) treated hemodialysis patients (+ACEi)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated hemodialysis patients (-ACEi)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pre-HD hemodialysis patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Post-HD hemodialysis patients
Number of subjects: 33
Study: 8896312

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 1985031

Group type: EXPERIMENTAL
Intervention: Pernicious anemia patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Asymptomatic control subjects
Number of subjects: 28
Study: 6846276

Group type: EXPERIMENTAL
Intervention: Quibron‐T/SR
Number of subjects: 13

Group type: COMPARATOR
Intervention: Theo‐Dur
Number of subjects: 13
Study: 31646953

Group type: EXPERIMENTAL
Intervention: High threat condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High efficacy condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low threat condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low efficacy condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficacy (high vs low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat (high vs low)
Number of subjects: 0
Study: 30766550

Group type: EXPERIMENTAL
Intervention: Aerobic exercises in addition to diet regimen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study: 27558249

Group type: EXPERIMENTAL
Intervention: Arthroscopic tennis elbow release (ECRB release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham lateral portal (no ECRB release)
Number of subjects: 0
Study: 24614337

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet plus exercise (LoGIX)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-glycemic index diet plus exercise (HiGIX)
Number of subjects: 27
Study: 22452841

Group type: EXPERIMENTAL
Intervention: Topicaine (4% lidocaine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Generic EMLA (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LMX-4 (4% lidocaine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BLT (20% benzoncaine, 6% lidocaine, and 4% tetracaine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LET (4% lidocaine, 1:2000 epinephrine, and 0.5% tetracaine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: OTC preparations (overall)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 4% lidocaine-containing preparations
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adverse reactions
Number of subjects: 25
Study: 20405046

Group type: EXPERIMENTAL
Intervention: Deterministic case definition of malaria caused fever (fever and parasite density above a certain cutoff)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic case definition of malaria caused fever (probability estimation of fever caused by malaria)
Number of subjects: 0
Study: 17565490

Group type: EXPERIMENTAL
Intervention: 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM)
Number of subjects: 132

Group type: COMPARATOR
Intervention: 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA)
Number of subjects: 132